Compare Enveric Biosciences Inc (ENVB) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wheaton Precious Metals Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Wheaton Precious Metals Corp trades at $138.27 (market cap $60.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 9094.2× Enveric Biosciences Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Wheaton Precious Metals Corp for 66 Days on average.
| ENVB | WPM | |
|---|---|---|
Market Cap | $6.69M | $60.84B |
Volume | 41,141 | 1,408,370 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $165.72 |
52-Week Low | $1.27 | $94.37 |
Typical Hold Time | 14 Days | 66 Days |
Enterprise Value | -$1.60M | $62.71B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Wheaton Precious Metals (WPM) trades at $134.96, down 1.95% on the day, amid a bearish technical signal. The company reported record revenues of $2.31B in 2025, with net income surging to $1.47B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive with strong analyst support—80% recommend Buy and a consensus price target of $164.80 implies 22% upside. Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock's current valuation multiples are elevated, but robust cash flow and margin expansion underpin the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
